| Acetyl-L-carnitine for alcohol craving and relapse prevention in anhedonic alcoholics: a randomized, double-blind, placebo-controlled pilot trial 2010 · ALC 1 g/day · Detoxified anhedonic patients with alcohol dependence | 1 g | 90 days | 21 |
| A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy 2013 · Acetyl-L-carnitine (ALC) arm · Adults with ovarian cancer or castration-resistant prostate cancer and no evidence of neuropathy | 333 mg | 18 weeks | 75 |
| A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia 2006 · ALCAR · Patients with pure dysthymia; age and sex not reported | 1 g | 12 weeks | — |
| Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS 2013 · ALC · Adults aged 40–70 with definite or probable amyotrophic lateral sclerosis (ALS), disease duration 6–24 months, self-sufficient, and forced vital capacity greater than 80% | 3 g | 48 weeks | 42 |
| Acetyl-L-carnitine for alcohol craving and relapse prevention in anhedonic alcoholics: a randomized, double-blind, placebo-controlled pilot trial 2010 · ALC 3 g/day · Detoxified anhedonic patients with alcohol dependence | 3 g | 90 days | 23 |
| Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial 2016 · ALC group · Men and women aged 18–70 with type 1 or type 2 diabetes and diabetic peripheral neuropathy | 1.5 g | 24 weeks | 117 |
| Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocele-associated oligoasthenospermia 2004 · group 3 · Adults with idiopathic or varicocele-associated oligoasthenospermia | 1 g | 26 weeks | 106 |
| Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocele-associated oligoasthenospermia 2004 · group 2 · Adults with idiopathic or varicocele-associated oligoasthenospermia | 1 g | 26 weeks | 101 |
| [A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia] 2005 · treatment group · men with oligoasthenozoospermia | 1 g | 90 days | 90 |
| Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study 2008 · group 1 (ALC) · Adults aged 29–85 with acute backache and moderate sciatica associated with a herniated disc | 1.18 g | 60 days | 33 |
| Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome 2004 · acetyl-L-carnitine group · people with chronic fatigue syndrome; age and sex not reported | 2 g | 24 weeks | 30 |
| Acetyl-L-carnitine in the treatment of mildly demented elderly patients 1990 · acetyl-L-carnitine group · Men and women over 65 years with mild mental impairment | 2 g | 90 days | 30 |
| Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report 2001 · acetyl-L-carnitine group · Patients with acute or initial chronic Peyronie's disease; ages and sex beyond the condition are not stated | 2 g | 90 days | 24 |
| Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression 1990 · L-acetylcarnitine group · Patients aged 70–80 years with depressive disturbance defined by DSM-III-R | 1.5 g | — | 14 |
| Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial 2004 · ALCAR · Patients with multiple sclerosis presenting with fatigue; ages and sex not specified | 2 g | 90 days | — |
| A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia 2004 · combined l-carnitine and l-acetyl-carnitine treatment · Infertile men aged 20–40 years with oligo-astheno-teratozoospermia and abnormal baseline sperm parameters | 1 g | 26 weeks | — |
| Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia 2005 · Combined L-carnitine and L-acetyl-carnitine · Men aged 20–40 years with idiopathic asthenozoospermia | 1 g | 26 weeks | — |
| Acetyl-L-carnitine in the management of pain during methadone withdrawal syndrome 2009 · ALC · Adults with methadone dependence undergoing detoxification | 2 g | 3 weeks | — |
| Role of acetyl-L-carnitine in the treatment of cognitive deficit in chronic alcoholism 1990 · LAC group · At least one-month-abstinent patients with chronic alcoholism and impaired performance in at least two of six mnemonic, praxic and verbal tasks | 2 g | 90 days | — |
| A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data 2015 · acetyl L-carnitine · female outpatients with fibromyalgia syndrome | 1.5 g | 12 weeks | — |
| Antioxidant treatment for oligoasthenoteratozoospermia and varicocele: a DBPC trial to evaluate the impact of age and body mass index 2024 · supplementation formulation (Proxeed Plus) · Men aged 18–50 years with infertility and oligo-, astheno- and/or teratozoospermia, with or without varicocele | 500 mg | 26 weeks | — |
| Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy 2013 · ALC · Women undergoing adjuvant taxane-based chemotherapy for breast cancer | 3 g | 24 weeks | 208 |
| Clinical Evidence of Acetyl-L-Carnitine Efficacy in the Treatment of Acute Ischemic Stroke: A Pilot Clinical Trial 2022 · ALC-treated group · Adults over 18 years, men and women, with a first-ever acute ischemic stroke and measurable neurological deficit, not eligible for thrombolysis or mechanical thrombectomy | 3 g | 3 days | 34 |
| Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study 2011 · ALC, HE1 group · Patients with overt hepatic encephalopathy, HE grade 1; age and sex not reported | 4 g | 90 days | 31 |
| Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study 2011 · ALC, HE2 group · Patients with overt hepatic encephalopathy, HE grade 2; age and sex not reported | 4 g | 90 days | 30 |
| Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial 2011 · ALC · Patients with severe hepatic encephalopathy; age and sex not specified | 4 g | 90 days | 30 |
| Idiopathic facial paralysis: new therapeutic prospects with acetyl-L-carnitine 1992 · Acetyl-L-carnitine group · Patients aged 11–67 with idiopathic facial paralysis; sex not specified by arm | 3 g | 30 days | — |
| Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia 2005 · L-acetyl-carnitine · Men aged 20–40 years with idiopathic asthenozoospermia | 3 g | 26 weeks | — |
| Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders 1990 · acetyl-L-carnitine group · Adults aged 60–80 with dysthymic disturbances | 3 g | 60 days | — |
| Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715) 2018 · ALC arm · Women undergoing adjuvant taxane-based chemotherapy for breast cancer | 3 g | 24 weeks | — |
| Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study 2023 · Group 2 · Adults with fibromyalgia | 1 g | 12 weeks | 62 |
| A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection 2007 · ALCAR · HIV-positive patients with symptomatic antiretroviral toxic neuropathy | 2 g | 8 weeks | 43 |
| Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome 2004 · acetyl-L-carnitine plus propionyl-L-carnitine group · people with chronic fatigue syndrome; age and sex not reported | 2 g | 24 weeks | 30 |
| Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study 2002 · LAC group · Patients with diabetic neuropathy; age and sex not reported | 2 g | 1 year | — |
| Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging 2004 · Group 2 · Men aged 60–74 with symptoms associated with male aging | 2 g | 26 weeks | — |
| Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients 2007 · LAC group · People with fibromyalgia meeting American College of Rheumatology criteria; age and sex not specified | 2.5 g | 10 weeks | — |
| Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia 2019 · Proxeed Plus · Men aged 19–44 with idiopathic oligoasthenozoospermia and difficulty conceiving with their partners for at least 12 months | 1 g | 26 weeks | 125 |
| [Using L- and acetyl-L-carnintines in combination with clomiphene citrate and antioxidant complex for treating idiopathic male infertility: a prospective randomized trial] 2017 · study group · Men aged 25–45 with idiopathic oligo-, astheno- and/or teratozoospermia | 1 g | 120 days | 88 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · NF group, 3-month blinded trial · Community-dwelling adults aged 18–86 years, both sexes, without dementia or clinical memory difficulties | 500 mg | 90 days | 59 |
| Combined Rehabilitation with Alpha Lipoic Acid, Acetyl-L-Carnitine, Resveratrol, and Cholecalciferolin Discogenic Sciatica in Young People: A Randomized Clinical Trial 2023 · Combo group (CG) · Adults aged 18–45 with acute sciatica due to lumbar disc herniation and low-back pain NRS 5–7 | 1 g | 30 days | 44 |
| Efficacy and Safety of the Combination of Superoxide Dismutase, Alpha Lipoic Acid, Vitamin B12, and Carnitine for 12 Months in Patients with Diabetic Neuropathy 2020 · Group A · Adults with type 2 diabetes, established peripheral and autonomic neuropathy, and at least four years of metformin treatment | 300 mg | 1 year | 43 |
| Combined Rehabilitation with Alpha Lipoic Acid, Acetyl-L-Carnitine, Resveratrol, and Cholecalciferolin Discogenic Sciatica in Young People: A Randomized Clinical Trial 2023 · Supplement group (SG) · Adults aged 18–45 with acute sciatica due to lumbar disc herniation and low-back pain NRS 5–7 | 1 g | 30 days | 41 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · Open-label NF group, separate 6-month trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties | 500 mg | 26 weeks | 38 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · NF group, 2-week blinded trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties | 500 mg | 2 weeks | — |
| Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials 2005 · 500 mg/day t.i.d. · Patients with established diabetic neuropathy; age and sex not specified | 500 mg | 52 weeks | — |
| Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials 2005 · 1,000 mg/day t.i.d. · Patients with established diabetic neuropathy; age and sex not specified | 1 g | 52 weeks | — |
| [Antioxidant therapeutic efficiency after the use of carnitine in infertile patients with bacterial or non bacterial prostato-vesiculo-epididymitis] 2001 · B1 · Infertile men with bacterial PVE, mean age 35 years (range 28–38) | 1 g | 90 days | 23 |
| [Antioxidant therapeutic efficiency after the use of carnitine in infertile patients with bacterial or non bacterial prostato-vesiculo-epididymitis] 2001 · B2 · Infertile men with bacterial PVE, mean age 35 years (range 28–38) | 1 g | 90 days | 16 |
| [Antioxidant therapeutic efficiency after the use of carnitine in infertile patients with bacterial or non bacterial prostato-vesiculo-epididymitis] 2001 · A1 · Infertile men with abacterial prostato-vesiculo-epididymitis (PVE), mean age 34 years (range 27–40) | 1 g | 90 days | 14 |
| [Antioxidant therapeutic efficiency after the use of carnitine in infertile patients with bacterial or non bacterial prostato-vesiculo-epididymitis] 2001 · B3 · Infertile men with bacterial PVE, mean age 35 years (range 28–38) | 1 g | 90 days | 12 |
| Effects of acetyl-L-carnitine oral administration on lymphocyte antibacterial activity and TNF-alpha levels in patients with active pulmonary tuberculosis. A randomized double blind versus placebo study 1991 · Acetyl-L-carnitine · Patients with active pulmonary tuberculosis; age and sex not stated | 2 g | 30 days | 10 |
| [Antioxidant therapeutic efficiency after the use of carnitine in infertile patients with bacterial or non bacterial prostato-vesiculo-epididymitis] 2001 · A2 · Infertile men with abacterial PVE, mean age 34 years (range 27–40) | 1 g | 90 days | 8 |
| [Antioxidant therapeutic efficiency after the use of carnitine in infertile patients with bacterial or non bacterial prostato-vesiculo-epididymitis] 2001 · A3 · Infertile men with abacterial PVE, mean age 34 years (range 27–40) | 1 g | 90 days | 8 |
| Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial 2021 · combo group · Women of reproductive age with PCOS | 3 g | 12 weeks | 72 |
| Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy 2011 · acetyl-L-carnitine group · Patients with minimal hepatic encephalopathy and cirrhosis; age and sex not reported | 4 g | 90 days | 33 |
| Acetyl-L-carnitine Slows the Progression from Prefrailty to Frailty in Older Subjects: A Randomized Interventional Clinical Trial 2022 · ALCAR group · Older prefrail subjects | 3 g | 90 days | — |